Lyme Disease: History and Discovery

Lyme disease is one of the few illnesses whose modern history can be traced almost month by month. It was brought to medical attention in 1975 by two determined mothers in the small towns of Lyme and Old Lyme, Connecticut, whose reports of an unusual cluster of childhood arthritis led Yale rheumatologist Dr. Allen Steere to define a new illness he first called “Lyme arthritis.” Its cause — a corkscrew-shaped spirochete bacterium carried by tiny Ixodes ticks — was identified in 1981–82 by the entomologist Willy Burgdorfer, and the organism, Borrelia burgdorferi, was named in his honor. Yet pieces of the puzzle had been described in Europe decades earlier, and a careful, honest account must also include the still-unsettled debate over “chronic Lyme disease.” This page tells that story as accurately as the evidence allows.

The European Prelude: Afzelius, Bannwarth, and the Bullseye Rash
The Connecticut Cluster of 1975
Allen Steere and the Naming of Lyme Disease
The Tick Hypothesis
Willy Burgdorfer and the Discovery of the Spirochete
Borrelia burgdorferi: Confirming the Cause
Diagnosis, Antibiotics, and a Treatable Disease
The “Chronic Lyme” and Post-Treatment Debate
Legacy and Ongoing Research
Research Papers and References
Connections

The European Prelude: Afzelius, Bannwarth, and the Bullseye Rash

Although Lyme disease is often described as “discovered” in the United States in the 1970s, several of its hallmark features were recorded in Europe far earlier. In 1909, at a meeting of the Swedish Society of Dermatology, the Swedish dermatologist Arvid Afzelius presented the first description of an expanding, ring-shaped skin lesion he had observed on a patient. He named it erythema chronicum migrans — literally “chronic migrating redness” — and, in work he published some years later, he speculated that the rash followed the bite of an Ixodes tick. This is the same bullseye rash, now called erythema migrans, that today is one of the most recognizable early signs of Lyme disease. Afzelius’s priority is permanently commemorated in the name Borrelia afzelii, one of the European bacterial species that causes the illness.

Over the following decades, European physicians described what we now recognize as the neurological face of the same infection. The German neurologist Alfred Bannwarth, writing in the 1940s, characterized a painful syndrome of nerve-root inflammation and meningitis — today remembered as Bannwarth syndrome and understood as a form of neuroborreliosis (Lyme disease of the nervous system). Other European clinicians linked tick bites to skin, joint, and nerve complaints, and a long-running European condition of the skin, acrodermatitis chronica atrophicans, would also later be tied to Borrelia infection. These observers, however, lacked the crucial final piece: no one had yet isolated the organism responsible, and the various skin, nerve, and joint presentations were not yet understood as different expressions of a single tick-borne infection.

This European prelude matters for accuracy. The 1975 American events did not reveal a brand-new disease so much as they brought a scattered, decades-old set of clues into sharp focus — and, critically, set in motion the hunt for the cause. It is fair to say that the clinical recognition of pieces of Lyme disease began in early-twentieth-century Europe, while the integration of those pieces into a named syndrome, and the eventual discovery of its cause, happened in late-twentieth-century America.

Back to Table of Contents

The Connecticut Cluster of 1975

The modern story begins not with a scientist but with worried parents. In the early 1970s, Polly Murray, a resident of Lyme, Connecticut, watched members of her own family — including her children — suffer recurring, unexplained episodes of swollen joints, rashes, fatigue, and fevers. Several local children, including two of Murray’s, had been given a diagnosis of juvenile rheumatoid arthritis, a condition that is not contagious and does not normally strike many children in one small community at once. Murray, who kept meticulous notes, became convinced that something unusual and possibly environmental was happening in her town, and she pressed health authorities to investigate. A second mother, Judith Mensch, independently raised the same alarm about her own child and other affected families.

In 1975 these reports reached the Connecticut State Department of Health, which recognized that an unusual cluster of juvenile arthritis — geographically concentrated in Lyme, Old Lyme, and neighboring East Haddam — warranted expert study. The state turned to the rheumatology group at the Yale School of Medicine. It is worth pausing on the historical point that the two people most responsible for getting Lyme disease noticed were not physicians at all, but two persistent mothers whose careful, documented observations would not be dismissed. Their advocacy is now a celebrated example of how patients and families can drive medical discovery.

The cluster had several striking features. Most of the affected people lived near wooded land; symptoms tended to begin in the warm months of summer and early fall; and the cases were grouped on the heavily wooded, deer-rich east side of the Connecticut River. These were not the patterns expected of ordinary juvenile arthritis, and they pointed strongly toward something in the environment that varied by season and by place — exactly the kind of pattern an infectious disease carried by an insect or tick would produce.

Back to Table of Contents

Allen Steere and the Naming of Lyme Disease

The investigation was led by Dr. Allen Steere, then a young rheumatologist at Yale, working with his senior colleague Dr. Stephen Malawista. Steere’s team systematically surveyed the affected towns in late 1975 and 1976 and assembled a series of cases — reported as 51 residents, a mix of children and adults — who shared a recognizable pattern of recurrent arthritis. Because the illness clustered around the town of Lyme, Steere named it “Lyme arthritis.” As it became clear that the joint inflammation was only one feature of a broader, multi-stage illness that could also involve the skin, heart, and nervous system, the name was broadened to the now-familiar “Lyme disease.”

Two clinical clues proved decisive in shifting the investigation from rheumatology toward infectious disease. First, many patients recalled a distinctive expanding rash — a bullseye — appearing weeks before their joints flared. Second, Steere and his colleagues recognized that this rash closely matched the erythema chronicum migrans that European dermatologists, beginning with Afzelius, had associated with tick bites decades earlier. Connecting the American cluster to that older European literature was a turning point: it suggested that Lyme arthritis was not a new and isolated mystery but a tick-transmitted infection, and it told investigators where to look for a cause.

Steere went on to become the central clinical figure in defining Lyme disease — describing its stages, its cardiac and neurological complications, and later its treatment. His careful epidemiological and clinical work through the late 1970s established Lyme disease as a distinct, reportable illness even before its microbial cause was known. In other words, the disease was clinically defined first and its germ found second — a sequence that shaped much of the controversy that would follow.

Back to Table of Contents

The Tick Hypothesis

By the late 1970s the evidence pointed insistently at ticks. The seasonal timing, the rural and wooded geography, the bullseye rash at the site of a bite, and the parallel to the European tick-associated erythema migrans all converged on the idea that a tick was the vector. Steere’s group specifically implicated the small Ixodes tick — the black-legged or “deer” tick — and field studies showed that the incidence of the disease tracked with the local abundance of these ticks. At this stage the tick hypothesis was exactly that: a strongly supported but still unproven hypothesis about how the disease spread, not yet an answer to what caused it.

It is important to keep these two questions separate, because their answers arrived at different times and from different scientists. By around 1977–1980 the medical community had reasonable confidence in the vector (an Ixodes tick) and a clear clinical picture of the disease, but the pathogen — the actual microbe transmitted by the tick — remained unidentified. Many candidates were considered over the years for erythema migrans and its complications, including viruses, rickettsiae, and toxins, before the true culprit was found.

The black-legged tick’s life cycle also explained the disease’s ecology. These ticks feed on small mammals such as the white-footed mouse and on white-tailed deer, and the postwar regrowth of forests and rebound of deer populations across the northeastern United States created ideal conditions for both the ticks and the infections they carried. This ecological framing — reforestation, abundant deer and mice, and expanding suburbs pushing people into tick habitat — remains the accepted explanation for why Lyme disease emerged as a major public-health problem in late-twentieth-century America.

Back to Table of Contents

Willy Burgdorfer and the Discovery of the Spirochete

The decisive breakthrough came from an unexpected direction and from a scientist who was not studying Lyme disease at all. Willy Burgdorfer (1925–2014) was a Swiss-born medical entomologist and an authority on tick-borne diseases at the Rocky Mountain Laboratories in Hamilton, Montana — a National Institutes of Health facility. In 1981, while dissecting Ixodes ticks collected in the northeastern United States as part of an investigation into a different infection (suspected Rocky Mountain spotted fever from ticks sent in connection with Shelter Island and Long Island, New York), Burgdorfer noticed something unexpected in the ticks’ midguts: long, coiled, spiral-shaped bacteria called spirochetes.

Burgdorfer’s expertise let him recognize at once that these spirochetes might be the long-sought cause of Lyme disease. The reasoning was compelling: spirochetes are the family of bacteria that includes the agent of syphilis, an illness that, like Lyme, unfolds in stages and can affect the skin, joints, heart, and nervous system; and finding them precisely in the Ixodes tick already suspected of transmitting Lyme disease tied the microbe to the vector. Working with colleagues, Burgdorfer showed that these spirochetes reacted with antibodies in the blood of Lyme disease patients — strong evidence that the patients’ immune systems had encountered this very organism.

The findings were published in the journal Science in 1982, in a paper (Burgdorfer and colleagues, including A. G. Barbour and J. L. Benach) memorably titled to pose the central question as a hypothesis — “Lyme disease — a tick-borne spirochetosis?” Within a short time the spirochete was successfully cultured and the question mark removed. It is historically precise to say that Burgdorfer first observed the spirochetes in 1981 and published the discovery in 1982; both years are correct for different steps of the same achievement, and the 1982 Science paper is the citable landmark.

Back to Table of Contents

Borrelia burgdorferi: Confirming the Cause

The newly identified spirochete was placed in the genus Borrelia and, in recognition of its discoverer, formally named Borrelia burgdorferi. The full causal case was assembled over the next few years by several groups: the organism was cultured from ticks, from the characteristic skin rash, and from the blood and other tissues of patients; patients with Lyme disease were shown to mount specific antibody responses against it; and treating patients with antibiotics active against the spirochete resolved the illness. Together these lines of evidence satisfied the classic criteria for establishing that a particular microbe causes a particular disease.

Later research refined the picture in ways that matter for both medicine and history. What is called Lyme disease is now known to be caused by several closely related members of the Borrelia burgdorferi sensu lato group. In North America the dominant agent is Borrelia burgdorferi in the strict sense (sensu stricto), whereas in Europe and Asia additional species such as Borrelia afzelii (named for Afzelius) and Borrelia garinii are common — which helps explain why the European illness, with its prominent skin and neurological forms, looks somewhat different from the arthritis-heavy American presentation that Steere first described. The vector ticks are members of the Ixodes genus: Ixodes scapularis (the black-legged or deer tick) and Ixodes pacificus in North America, and Ixodes ricinus in Europe.

With the cause established, the disease could at last be approached as a defined bacterial infection: it could be diagnosed with blood tests that detect the antibody response, studied microbiologically, and — most importantly for patients — treated and often cured with antibiotics. The transformation from a baffling cluster of childhood arthritis in 1975 to a named, culturable, treatable bacterial infection within roughly a decade is one of the more rapid and complete disease-discovery stories in modern medicine.

Back to Table of Contents

Diagnosis, Antibiotics, and a Treatable Disease

Once Borrelia burgdorferi was identified, the practical consequences followed quickly. Because the organism is a bacterium, it is susceptible to antibiotics, and clinical studies established that appropriate antibiotic treatment reliably cures early Lyme disease and resolves most later complications. For most patients the cornerstone oral drug is doxycycline, with amoxicillin and cefuroxime as alternatives (for example in young children or pregnancy); more serious forms involving the nervous system or heart may be treated with intravenous antibiotics such as ceftriaxone. Treated early — ideally at the erythema migrans rash stage — Lyme disease has an excellent prognosis.

Diagnosis evolved alongside treatment. Because the spirochete is difficult to find directly in the blood, routine testing relies chiefly on detecting the body’s antibody response, conventionally through a two-tiered approach (a screening immunoassay followed by a confirmatory test). These antibody tests have real limitations — they can be falsely negative in the first weeks of infection before antibodies develop, and a positive result reflects past exposure rather than necessarily active infection — nuances that feed directly into the controversies discussed below. The classic bullseye erythema migrans rash, when present, remains so characteristic that it can support a clinical diagnosis without waiting for blood tests.

Prevention has likewise been shaped by the discovery of the tick vector: avoiding tick habitat, using repellents, wearing protective clothing, performing prompt tick checks, and removing attached ticks quickly all reduce risk, because Ixodes ticks generally must remain attached for many hours to transmit the spirochete. A human Lyme vaccine (LYMErix) was licensed in the United States in 1998 but withdrawn from the market in 2002 amid disappointing sales and public concern; the development of newer vaccine candidates is an active area of research today. (Practical, up-to-date details on testing, treatment, prevention, and tick removal are covered in this site’s companion Lyme disease articles, linked in the Connections section below.)

Back to Table of Contents

The “Chronic Lyme” and Post-Treatment Debate

No honest history of Lyme disease can omit its most painful controversy, and it deserves to be presented carefully and factually. A subset of patients who have been treated for Lyme disease with a standard, recommended course of antibiotics continue to report lingering symptoms — most often fatigue, musculoskeletal pain, and difficulties with memory and concentration — that can persist for months. When these symptoms are well documented after a confirmed infection and adequate treatment, the medical literature refers to post-treatment Lyme disease syndrome (PTLDS). That such ongoing symptoms are real, and genuinely disabling for some people, is not in dispute. What is debated — and remains scientifically unsettled — is what causes them and how best to treat them.

The flashpoint is the popular but contested term “chronic Lyme disease.” Some clinicians and patient advocates use it to mean an ongoing, active Borrelia infection that has persisted despite treatment (or that was never diagnosed), and on that theory they prescribe prolonged courses of antibiotics, sometimes for months or years. Mainstream infectious-disease bodies, including the Infectious Diseases Society of America, take a different view: they emphasize that, in patients who have received standard treatment, there is no convincing microbiological evidence of an ongoing active infection, and — crucially — that the question has been tested directly. Several rigorous randomized, placebo-controlled trials of long-term antibiotics for persistent symptoms attributed to Lyme disease (notably the Klempner trials reported in 2001 and the European PLEASE trial reported in 2016) found no meaningful, lasting benefit over placebo, while long-term intravenous antibiotics carry real risks, including serious bloodstream and intravenous-line complications.

The fairest factual summary is this: (1) persistent post-treatment symptoms are real and can be severe; (2) the cause of those symptoms — whether lingering immune activation, tissue damage, residual non-replicating bacteria, an unrelated condition, or some combination — is genuinely uncertain and under active study; and (3) the specific claim that long courses of antibiotics are an effective treatment is not supported by the controlled trials conducted to date, which is why major guidelines advise against them. Patients with debilitating ongoing symptoms deserve to be believed and helped; that compassion, however, is separate from the empirical question of whether prolonged antibiotics work, and on that narrow question the trial evidence is consistent and discouraging. Research into the biological basis of PTLDS — and into better treatments for it — continues.

Back to Table of Contents

Legacy and Ongoing Research

In barely a decade, Lyme disease went from an unexplained cluster of childhood arthritis to a fully characterized, treatable bacterial infection — an unusually clean arc of medical discovery. The names attached to that arc are now permanent fixtures of the field: the disease and the town of Lyme, Connecticut; the bacterium Borrelia burgdorferi and its discoverer Willy Burgdorfer; the European species Borrelia afzelii and Borrelia garinii honoring earlier observers; and the clinical definition of the illness owed to Allen Steere and his Yale colleagues. The story is also a landmark in patient advocacy, because none of it would have begun without Polly Murray and Judith Mensch refusing to accept that nothing unusual was happening to their children.

Lyme disease today is the most common vector-borne illness in the United States and a growing problem across the Northern Hemisphere, and its geographic range has expanded as tick populations spread — a trend many researchers link to changing land use and climate. That expansion keeps the science urgent. Active areas of research include better and earlier diagnostic tests that can detect infection before antibodies appear, new human vaccines (and even vaccines aimed at the ticks or their animal hosts), the biology of how the spirochete evades the immune system, and the still-open question of what drives post-treatment symptoms.

For the general reader, the most important lessons of this history are practical and hopeful: Lyme disease is caused by a known bacterium, spread by a known tick, and — especially when caught early — cured by ordinary antibiotics. The prevention measures that work follow directly from understanding the tick’s life cycle. And the genuine uncertainties that remain, particularly around lasting symptoms, are best met with honesty rather than overclaiming in either direction — which is exactly the spirit in which the disease was discovered.

Back to Table of Contents

Research Papers and References

The references below combine landmark peer-reviewed papers in the discovery and clinical history of Lyme disease with curated PubMed topic-search links into the historical, microbiological, and treatment literature. Each external link opens at its source (PubMed/National Library of Medicine, a journal, or an authoritative public-health resource) in a new tab. Where a specific historical paper is named, real identifiers are given; broader themes link to PubMed topic searches.

Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease — a tick-borne spirochetosis? Science. 1982;216(4552):1317-1319. — doi:10.1126/science.7043737
Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis & Rheumatism. 1977;20(1):7-17. — doi:10.1002/art.1780200102
Steere AC. Lyme disease. New England Journal of Medicine. 2001;345(2):115-125. — doi:10.1056/NEJM200107123450207
Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nature Reviews Disease Primers. 2016;2:16090. — doi:10.1038/nrdp.2016.90
Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine. 2001;345(2):85-92. — doi:10.1056/NEJM200107123450202
Berende A, ter Hofstede HJM, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease (PLEASE trial). New England Journal of Medicine. 2016;374(13):1209-1220. — doi:10.1056/NEJMoa1505425
Burgdorfer W. How the discovery of Borrelia burgdorferi came about. Clinics in Dermatology. 1993;11(3):335-338. — PubMed: discovery of Borrelia burgdorferi (Burgdorfer)
Arvid Afzelius and the 1909 description of erythema chronicum migrans — PubMed: Afzelius erythema chronicum migrans history
Bannwarth syndrome and the history of Lyme neuroborreliosis — PubMed: Bannwarth syndrome neuroborreliosis history
History and discovery of Lyme disease in Connecticut (Steere, Yale) — PubMed: Lyme disease history and discovery
Borrelia burgdorferi sensu lato species and geographic variation — PubMed: Borrelia burgdorferi sensu lato species
Post-treatment Lyme disease syndrome (PTLDS) — mechanisms and evidence — PubMed: post-treatment Lyme disease syndrome
Antibiotic treatment of Lyme disease and treatment guidelines — PubMed: Lyme disease antibiotic treatment guidelines
Ixodes scapularis, deer, and the ecology of Lyme disease emergence — PubMed: Ixodes ecology of Lyme disease

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents